Drug Profile
Research programme: cancer immunotherapeutics - IOmet Pharma
Alternative Names: Dual IDO/TDO inhibitors - IOmet Pharma; IDO inhibitors - IOmet Pharma; TDO inhibitors - IOmet PharmaLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator IOmet Pharma
- Class Small molecules
- Mechanism of Action Immunostimulants; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Cancer in United Kingdom (PO)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 16 Apr 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)